-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, the U.
BNT162b2 is a new coronavirus vaccine based on mRNA technology.
In a phase 3 clinical trial involving 2260 adolescents aged 12-15 years, 18 COVID-19 patients with symptoms were found in the placebo group (n=1129), but none in the vaccine group (n=1131) Symptoms of COVID-19 patients.
At the same time, BNT162b2 is well tolerated in this adolescent population, and the side effects are comparable to those previously observed in 16-25 year olds.
This vaccine should not be given to anyone with a known history of severe allergic reactions (including allergic reactions to any component of the vaccine).
Note: The original text has been deleted
Reference materials:
[1] Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic.
